🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 00901B105 (prev. 42366C509 )
- Market Cap
- Micro Cap
- Previous Symbol
- HEB (changed 9/3/2019)
- Previous Name
- Hemispherx Biopharma, Inc.
Business: AIM ImmunoTech Inc., is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Notes: May 31, 2019 -- Hemispherx Biopharma, Inc. (NYSE American: HEB), Following the stockholder vote, the Board met and approved a 1-for-44 reverse stock split to achieve a value of approximately $5 per share. The Company anticipates that the reverse stock split will be effective on June 10, 2019, and the Company's common stock will begin trading on a split-adjusted basis on June 11, 2019. ____________ Aug 17 2016 -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it will effect a 1-for-12 reverse stock split of its common stock. The reverse stock split will reduce the number of shares of the Company's common stock currently outstanding from approximately 248,932,220 shares to approximately 20,744,352 shares. All resulting fractional shares will be rounded up to the next whole share.
Company Contact
- CEO
- Thomas K. Equels
- CFO
- Robert Dickey IV
- Headquarters
- 2117 SW Highway 484, Ocala FL 34473
- Phone
- 352-448-7797 · Toll-Free 800-778-4042
- Investor Relations
- 800-778-4042 · IR@aimimmuno.com